UroGen Pharma Ltd. stock is up 13.14% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.
UroGen Pharma Ltd. engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs. The company's lead product candidate is UGN-102, which is in Phase III clinical trials.